nach oben

Lung

Erschienen in:

24.03.2020 | COPD

Correlations Between Serum Decoy Receptor 3 and Airflow Limitation and Quality of Life in Male Patients with Stable Stage and Acute Exacerbation of COPD

verfasst von: Hassan Ghobadi, Nima Hosseini, Mohammad Reza Aslani

Erschienen in: Lung | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Serum decoy receptor 3 (DcR3) level increases in chronic inflammatory diseases. The present study aimed to examine serum DcR3 and IL-6 levels in male patients with stable chronic obstructive pulmonary disease (COPD) and acute exacerbation of the disease and correlations between these markers and airflow limitation.

Methods

We measured serum DcR3 and IL-6 levels in 60 COPD patients [30 stable COPD (SCOPD), and 30 acute exacerbation of COPD (AECOPD)], and 30 control subjects and assessed their correlations with airflow limitation according to the COPD stage indicated by the global initiative for chronic obstructive pulmonary disease (GOLD) criteria, peripheral O₂ saturation (SpO₂), and COPD assessment test (CAT) score. We also tested associations between serum DcR3 levels and COPD patients’ clinical parameters.

Results

Both serum DcR3 and IL-6 levels increased with increasing severity of airflow limitation in SCOPD and AECOPD groups (P < 0.01 to 0.001). These markers also increased in patients with AECOPD compared with subjects in SCOPD group in GOLD stages III–IV (P < 0.05 to 0.001). In addition, there was a significant positive correlation between serum DcR3 level and IL-6, CAT score and smoking history (per year).

Conclusion

The study revealed that serum DcR3 level elevated with increasing severity of airflow limitation in male COPD patients, particularly in acute exacerbation phase. This increase was associated with a reduced quality of life and increased severity of hypoxia. These results suggest that DcR3 may be associated with the underlying pathophysiology of COPD in male patients.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DM, Han M (2019) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. https://doi.org/10.1183/13993003.00164-2019 CrossRefPubMedPubMedCentral

Celli BR, Barnes PJ (2007) Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 29(6):1224–1238. https://doi.org/10.1183/09031936.00109906 CrossRefPubMed

Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH (2007) Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc 4(8):626–634. https://doi.org/10.1513/pats.200706-071TH CrossRefPubMed

Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA (2006) Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173(1):71–78. https://doi.org/10.1164/rccm.200505-704OC CrossRefPubMed

Lin W-W, Hsieh S-L (2011) Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 81(7):838–847. https://doi.org/10.1016/j.bcp.2011.01.011 CrossRefPubMed

Cheng C-P, Sytwu H-K, Chang D-M (2011) Decoy receptor 3 attenuates collagen-induced arthritis by modulating T cell activation and B cell expansion. J Rheumatol 38(12):2522–2535. https://doi.org/10.3899/jrheum.110245 CrossRefPubMed

Chang Y-C, Hsu T-L, Lin H-H, Chio C-C, Chiu AW, Chen N-J, Lin C-H, Hsieh S-L (2004) Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 75(3):486–494. https://doi.org/10.1189/jlb.0903448 CrossRefPubMed

Mueller AM, Pedré X, Killian S, David M, Steinbrecher A (2009) The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol 209(1):57–64. https://doi.org/10.1016/j.jneuroim.2009.01.024 CrossRefPubMed

Hung SC, Hsu TW, Lin YP, Tarng DC (2012) Decoy receptor 3, a novel inflammatory marker, and mortality in hemodialysis patients. Clin J Am Soc Nephrol 7(8):1257–1265. https://doi.org/10.2215/cjn.08410811 CrossRefPubMedPubMedCentral

10.

Yang C-R, Hsieh S-L, Ho F-M, Lin W-W (2005) Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-κB-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J Immunol 174(3):1647–1656. https://doi.org/10.4049/jimmunol.174.3.1647 CrossRefPubMed

11.

Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W (2005) Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol 25(6):1256–1261. https://doi.org/10.1161/01.ATV.0000166517.18801.a7 CrossRefPubMed

12.

Chen M-H, Kan H-T, Liu C-Y, Yu W-K, Lee S-S, Wang J-H, Hsieh S-L (2017) Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients. J Formos Med Assoc 116(1):49–56. https://doi.org/10.1016/j.jfma.2016.01.007 CrossRefPubMed

13.

Gao L, Yang B, Zhang H, Ou Q, Lin Y, Zhang M, Zhang Z, Kim S, Wu B, Wang Z, Fu L, Lin J, Chen R, Lan R, Chen J, Chen W, Chen L, Zhang H, Han D, Chen J, Okunieff P, Lin J, Zhang L (2018) DcR3, a new biomarker for sepsis, correlates with infection severity and procalcitonin. Oncotarget 9(13):10934–10944. https://doi.org/10.18632/oncotarget.23736 CrossRefPubMed

14.

Chen C-Y, Yang K-Y, Chen M-Y, Chen H-Y, Lin M-T, Lee Y-C, Perng R-P, Hsieh S-L, Yang P-C, Chou T-Y (2009) Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am J Respir Crit 180(8):751–760. https://doi.org/10.1164/rccm.200902-0222OC CrossRef

15.

Funke B, Autschbach F, Kim S, Lasitschka F, Strauch U, Rogler G, Gdynia G, Li L, Gretz N, Macher-Goeppinger S, Sido B, Schirmacher P, Meuer SC, Roth W (2009) Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 58(4):483–491. https://doi.org/10.1136/gut.2008.148908 CrossRefPubMed

16.

Dong Y, Shi D, Li M, Dai P, Wang X, Xie M (2015) Elevated serum levels of decoy receptor 3 are associated with disease severity in patients with hemorrhagic fever with renal syndrome. Intern Emerg Med 10(5):567–573. https://doi.org/10.1007/s11739-015-1195-7 CrossRefPubMedPubMedCentral

17.

Lee CS, Hu CY, Tsai HF, Wu CS, Hsieh SL, Liu LC, Hsu PN (2008) Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol 151(3):383–390. https://doi.org/10.1111/j.1365-2249.2007.03579.x CrossRefPubMedPubMedCentral

18.

Chang T-Y, Hsu C-Y, Huang P-H, Chiang C-H, Leu H-B, Huang C-C, Chen J-W, Lin S-J (2015) Usefulness of circulating decoy receptor 3 in predicting coronary artery disease severity and future major adverse cardiovascular events in patients with multivessel coronary artery disease. Am J Cardiol 116(7):1028–1033. https://doi.org/10.1016/j.amjcard.2015.06.041 CrossRefPubMed

19.

Hsieh SL, Lin WW (2017) Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions. J Biomed Sci 24(1):39. https://doi.org/10.1186/s12929-017-0347-7 CrossRefPubMedPubMedCentral

20.

Zhou A, Zhou Z, Peng Y, Zhao Y, Duan J, Chen P (2018) The role of CAT in evaluating the response to treatment of patients with AECOPD. Int J Chronic Obstr Pulm Dis 13:2849–2858. https://doi.org/10.2147/copd.s175085 CrossRef

21.

Amani M, Ghadimi N, Aslani MR, Ghobadi H (2017) Correlation of serum vascular adhesion protein-1 with airflow limitation and quality of life in stable chronic obstructive pulmonary disease. Respir Med 132:149–153. https://doi.org/10.1016/j.rmed.2017.10.011 CrossRefPubMed

22.

Hogg JC (2004) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364(9435):709–721. https://doi.org/10.1016/s0140-6736(04)16900-6 CrossRef

23.

Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350(26):2645–2653. https://doi.org/10.1056/NEJMoa032158 CrossRefPubMed

24.

Barnes PJ (2016) Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 138(1):16–27. https://doi.org/10.1016/j.jaci.2016.05.011 CrossRefPubMed

25.

Liang R, Zhang W, Song YM (2013) Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models. Mol Med Rep 7(5):1470–1476. https://doi.org/10.3892/mmr.2013.1377 CrossRefPubMed

26.

Foschino Barbaro MP, Carpagnano GE, Spanevello A, Cagnazzo MG, Barnes PJ (2007) Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol 20(4):753–763. https://doi.org/10.1177/039463200702000411 CrossRefPubMed

27.

Kim S, McAuliffe WJ, Zaritskaya LS, Moore PA, Zhang L, Nardelli B (2004) Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect Immun 72(1):89–93. https://doi.org/10.1128/IAI.72.1.89-93.2004 CrossRefPubMedPubMedCentral

28.

Ortiz A, Lorz C, Justo P, Catalan MP, Egido J (2001) Contribution of apoptotic cell death to renal injury. J Cell Mol Med 5(1):18–32. https://doi.org/10.1111/j.1582-4934.2001.tb00135.x CrossRefPubMedPubMedCentral

29.

Watz H, Waschki B, Meyer T, Magnussen H (2009) Physical activity in patients with COPD. Eur Respir J 33(2):262–272CrossRef

30.

Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, Meyer T, Holz O, Magnussen H (2009) The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 136(4):1039–1046. https://doi.org/10.1378/chest.09-0393 CrossRefPubMed

Titel: Correlations Between Serum Decoy Receptor 3 and Airflow Limitation and Quality of Life in Male Patients with Stable Stage and Acute Exacerbation of COPD
verfasst von: Hassan Ghobadi
Nima Hosseini
Mohammad Reza Aslani
Publikationsdatum: 24.03.2020
Verlag: Springer US
Erschienen in: Lung / Ausgabe 3/2020
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-020-00348-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Correlations Between Serum Decoy Receptor 3 and Airflow Limitation and Quality of Life in Male Patients with Stable Stage and Acute Exacerbation of COPD

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Cardio-Pulmonary Changes After Bronchoscopic Lung Volume Reduction with Endobronchial One-Way Valves

Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy

Obesity Predicts Treatment Response to Proton Pump Inhibitor Therapy in Patients with Chronic Cough

Age-Dependent Progression in Lung Pathophysiology can be Prevented by Restoring Fatty Acid and Ceramide Imbalance in Cystic Fibrosis

Risk of Future Type 2 Diabetes Mellitus in Patients Developing Steroid-Induced Hyperglycemia During Hospitalization for Chronic Obstructive Pulmonary Disease Exacerbation

Elevated Circulating CD4+CD25+CD127−/low Regulatory T Cells in Patients with Non-asthmatic Eosinophilic Bronchitis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin